A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim ...

Deficiency of ADAMTS13 plays a critical role in platelet accumulation in PA-ILI, suggesting that ADAMTS13 could be a potential therapeutic target for this condition.

TAK-755 is a recombinant version of the ADAMTS13 protein designed to replace the missing enzyme, which was given in the pivotal study as an intravenous infusion once every week or every other week.